Accurate Education - How Taurine Impacts Pain Processing

Pain Processing:

How Taurine Impacts Pain Processing

Taurine acts as an inhibitory neurotransmitter and neuromodulator in the central nervous system, providing significant analgesic effects on neuropathic, inflammatory, and acute pain. It functions by activating nerve receptors and reducing nerve hyperexcitability. It also has antioxidant properties, particularly at spinal and peripheral levels.

See:

Taurine for Chronic Pain: A Patient Guide

How Nutraceuticals Impact Pain Processing

Pain Processing

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

How Taurine Impacts Pain Processing

Introduction to Taurine

Taurine is an amino acid that represents one of the most abundant free amino acids in mammalian tissues, with particularly high concentrations in the brain, retina, heart, and skeletal muscle.[1][2] Unlike most amino acids, taurine is not incorporated into proteins but exists as a free intracellular molecule where it participates in numerous physiological processes including membrane stabilization, calcium homeostasis, neurotransmission, and antioxidant defense.[1][2]

Taurine is primarily synthesized in the liver and kidney from cysteine, though dietary intake from seafood and meat sources is required to meet physiological needs.[3][4] Brain concentrations of taurine decrease with age, which has implications for neurological function and pain processing.[3]

Nutraceuticals, including taurine, offer a broad spectrum of pharmacological actions relevant to the process of sending pain signals from an area of injury to the brain, culminating in the experience of pain. Nutraceuticals impact the processing of pain signaling based on its different properties, including anti-inflammatory, antioxidant, and neuroprotective properties.

Pain Processing involves complex nerve interactions that:

Starts with the detection of damaged tissues by specialized pain receptors,
Followed by sending pain signals to the spinal cord through peripheral nerves, then
Processing of the signals in the spinal cord, then
Forwarding the signals up ascending pain pathways to various parts of the brain, then
Processing of the pain signals in the brain (supraspinal integration)
Followed, finally, by the brain sending pain signals back down descending pain pathways in the spinal cord to impact the pain signal processing in the spinal cord (descending pain modulation).

At each of these stages, or levels, of pain processing, the pain signaling can be modified referred to as pain modulation. Pain modulation can result in the pain experience being magnified or suppressed, temporarily or in some cases permanently. There are many situations and processes that modulate the pain experience, but the focus here is limited to the magnification of pain that occurs in the pathologic processing of pain signals in nerves in the peripheral nervous system and/or the spinal cord and brain (the central nervous system).

This pathologic pain processing that results in heightened sensitivity and magnification of the pain experience, it is referred to as “Sensitization) which can originate in peripheral and or central nervous system, termed “Peripheral Sensitization” and “Central Sensitization.”

Central to the pathophysiology of pain processing leading to Peripheral Sensitization and Central Sensitization are 4 interconnected conditions, sometimes referred to as “the 4 Demons of Pain:”

Systemic Inflammation
Neuroinflammation’ below
Oxidative Stress
Mitochondrial Dysfunction.

Section 1: Overview of Taurine in Context of Pain Processing

Taurine’s Impact on the Four Key Processes Affecting Pain Processing

1. Systemic Inflammation

Taurine demonstrates significant anti-inflammatory properties through multiple molecular mechanisms. A systematic review and dose-response meta-analysis of controlled trials found that taurine supplementation significantly reduces C-reactive protein (a biomarker for systemic inflammation), with optimal effects observed after 8 weeks (56 days) of supplementation.[6] A more recent meta-analysis of 34 randomized controlled trials confirmed these findings, demonstrating significant reductions in CRP.[7]

The anti-inflammatory mechanisms of taurine include:

1. NF-κB pathway inhibition: Taurine suppresses nuclear factor kappa B (NF-κB) transcription and subsequent production of pro-inflammatory mediators including TNF-α, IL-6, and IL-18. In experimental colitis models, taurine binds directly to TLR4 and inhibits the TLR4/NF-κB pathway.[8][9]
2. MAPK signaling modulation: Taurine regulates mitogen-activated protein kinase (MAPK) signaling, including ERK1/2, JNK, and p38 pathways, which are involved in inflammatory responses.[8][10]
3. Taurine chloramine formation: In activated neutrophils, taurine reacts with hypochlorous acid to form taurine chloramine (TauCl), which has potent anti-inflammatory properties and triggers the Keap1-Nrf2 pathway.[1][11]
4. Cytokine modulation: Taurine reduces production of pro-inflammatory cytokines including IL-6, TNF-α, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2).[12][13]

2. Neuroinflammation

Taurine exerts potent anti-neuroinflammatory effects primarily through modulation of microglial activation, which is a key driver of neuroinflammation in chronic pain states and neurodegenerative conditions.

1. Microglial M1 polarization inhibition: In Parkinson’s disease models, taurine protects dopaminergic neurons by inhibiting microglial M1 polarization through suppression of NADPH oxidase (NOX2) activation and NF-κB pathway inhibition. Taurine interferes with membrane translocation of the cytosolic subunit p47phox, preventing NOX2 assembly and activation.[13]
2. Epigenetic regulation: Taurine inhibits lysine demethylase 3a (KDM3a) production in microglia, increasing H3K9 methylation levels (H3K9me1/2/3) and reducing inflammatory factor generation. This epigenetic mechanism represents a novel pathway for taurine’s anti-neuroinflammatory effects.[12]
3. TREM2 upregulation: In senescence-accelerated mice, taurine upregulates triggering receptor expressed on myeloid cells-2 (TREM2), which protects against microglial over-activation and reduces accumulation of phosphorylated tau and amyloid-β.[14]
4. Astrocyte-mediated neuroprotection: Taurine is synthesized predominantly in astrocytes within the CNS and is released as a gliotransmitter. Astrocytes provide neurons with hypotaurine as a substrate for neuronal taurine production, establishing a metabolic coupling that supports neuroprotection.[3]
5. Attenuation of reactive gliosis: In cerebral ischemia models, taurine supplementation significantly mitigates ischemia-induced reactive astrocytosis and microgliosis, downregulating NFκB activation and MAPK cascade components (ERK, JNK, p38).[10]

3. Oxidative Stress

Taurine functions as a critical regulator of cellular redox homeostasis through both direct and indirect antioxidant mechanisms.

Direct Antioxidant Effects:

The direct free radical scavenging capacity of taurine is limited and primarily relevant in tissues with very high taurine concentrations (>15-20 mM), such as the heart and retina.[11]
Taurine chloramine formation in activated neutrophils provides localized antioxidant protection.[1][11]

Indirect Antioxidant Effects:

Nrf2 pathway activation: Taurine chloramine triggers the Keap1-Nrf2 pathway, inducing expression of antioxidant genes including heme oxygenase-1 (HO-1), catalase, and NAD(P)H quinone oxidoreductase-1 (NQO-1).[8][1]
Glutathione enhancement: Taurine enhances glutathione (GSH) levels, which is crucial for detoxifying harmful substances and maintaining cellular redox balance.[15][16]
Lipid peroxidation reduction: Meta-analysis demonstrates that taurine supplementation significantly reduces malondialdehyde (MDA) levels (SMD = -1.17 µmol/L; 95% CI: -2.08 to -0.26; P = 0.012), indicating decreased lipid peroxidation.[6][7]
Antioxidant enzyme upregulation: Taurine upregulates superoxide dismutase (SOD), including mitochondrial SOD2, and glutathione peroxidase 4 (GPX4).[8][10]
ROS-producing enzyme inhibition: Taurine inhibits ROS-generating enzymes, including components of NADPH oxidase, reducing oxidative stress at its source.[11][13]

4. Mitochondrial Dysfunction

Taurine plays a fundamental role in maintaining mitochondrial health and function, which is critical for cellular energy production and prevention of oxidative damage.

Electron transport chain stabilization: Taurine deficiency compromises the electron transport chain in mitochondria and significantly increases free radical production. Maintaining optimal taurine status in mitochondria helps control free radical generation at its primary source.[11][17]
Mitochondrial taurine content: Taurine transporter knockout mice show a 60% decrease in mitochondrial taurine content, associated with diminished complex I activity and onset of mitochondrial oxidative stress.[18]
Prevention of mitochondria-dependent apoptosis: Taurine deficiency triggers overproduction of reactive oxygen species by complex I of the respiratory chain, leading to mitochondria-dependent apoptosis through activation of caspases 9 and 3. Treatment with the mitochondria-specific antioxidant MitoTempo prevents this caspase activation, confirming the mitochondrial origin of the oxidative stress.[18]
Energy homeostasis maintenance: Taurine protects mitochondrial function by preventing oxidative stress and maintaining energy homeostasis. Taurine-deficient mice exhibit impaired exercise performance related to compromised mitochondrial bioenergetics.[15][17][1]
Calcium homeostasis: Taurine regulates intracellular calcium levels, preventing calcium overload that can trigger mitochondrial stress and apoptosis.[15][3][16]
ER stress modulation: In aging taurine-deficient mice, endoplasmic reticulum (ER) stress contributes to cell death through caspase 12 activation, indicating taurine’s role in maintaining ER function alongside mitochondrial health.[18]

Section 2: Pain Processing Pathway Analysis (Levels 1-6)

This section provides a detailed analysis of how taurine impacts each level of the pain processing pathway, from peripheral pain receptors through descending modification.

Level 1: Peripheral Nociception (Pain Receptor Transduction):

TRPV1 Channel Modulation

Taurine demonstrates regulatory effects on transient receptor potential vanilloid-1 (TRPV1) channels, which are critical for nociceptor activation. Studies in human keratinocytes and C. elegans models demonstrate that taurine inhibits TRPV-dependent activity, reducing calcium influx activated by TRPV1 agonists and attenuating oxidative stress responses.[1] Notably, N-acyl taurine (NAT), an endogenous taurine derivative, activates TRPV1 channels, while taurine itself appears to have regulatory effects on this activation.[2] In the prefrontal cortex, taurine (as a decomposition product of NAT) strongly depresses evoked glutamatergic synaptic transmission, suggesting complex modulatory roles.[2]

Peripheral Sensory Neuron Effects

Taurine exerts significant effects on dorsal root ganglion (DRG) sensory neurons:

1. Calcium homeostasis regulation: In diabetic neuropathy models, taurine replacement corrects abnormal intracellular calcium signaling in small DRG sensory neurons. Recovery of intracellular Ca²⁺ concentration in response to KCl stimulation was 73% corrected by taurine supplementation.[3]
2. Attenuation of hyperalgesia: Taurine replacement in diabetic rats prevented reductions in mechanical and thermal withdrawal thresholds, indicating reduced peripheral sensitization.[3]
3. Muscarinic receptor involvement: Taurine induces analgesia at peripheral levels through cholinergic mechanisms involving muscarinic receptors. The combination of taurine with sodium salicylate produces more potent analgesia than either agent alone, mediated via peripheral muscarinic receptor activity.[4]

Anti-inflammatory Effects at Peripheral Nociceptors

Taurine reduces peripheral sensitization through:

1. Inhibition of pro-inflammatory cytokine production (TNF-α, IL-6) that sensitize nociceptors[5][6]
2. Reduction of COX-2 expression and prostaglandin synthesis[7]
3. Attenuation of oxidative stress that contributes to nociceptor sensitization[5][8]

Level 2: Primary Afferent Transmission to Spinal Cord

Taurine significantly impacts primary afferent nerve function and transmission to the spinal cord.

Nerve Conduction and Axonal Function

Taurine plays a critical role in maintaining normal nerve conduction:

1. Prevention of conduction velocity deficits: In diabetic neuropathy models, taurine supplementation (1% dietary) prevented motor nerve conduction velocity (NCV) slowing and digital sensory NCV deficits. Two weeks of diabetes reduced sciatic motor NCV by 23%, which was corrected by taurine supplementation.[9]
2. Axonal protection: Taurine ameliorates axonal damage in sciatic nerve of diabetic rats through activation of the PI3K/Akt/mTOR signaling pathway, improving dysfunctional nerve conduction and correcting damaged axonal morphology.[10]
3. Myelin protection: Taurine protects against myelin damage by controlling Schwann cell apoptosis via the NGF/Akt/GSK3β pathway, preserving the structural integrity necessary for efficient signal transmission.[11]

Membrane Stabilization and Excitability Modulation

Taurine modulates axonal membrane properties:

1. Chloride and potassium conductance: Taurine increases membrane permeabilities to potassium and chloride (but not sodium), causing the membrane potential to stabilize near resting levels. This results in a reversal potential for the taurine response at approximately -85 mV.[12]
2. Action potential modulation: Taurine reduces action potential duration, primarily through acceleration of the repolarization phase, contributing to membrane stabilization.[12]
3. Osmolyte function: Taurine functions as a compatible osmolyte in peripheral nerve. Diabetes-induced sorbitol accumulation leads to reciprocal taurine depletion, contributing to nerve dysfunction. Aldose reductase inhibition increases nerve taurine levels by 22%.[13]

Localization in Primary Afferents

Immunohistochemical studies demonstrate taurine-like immunoreactivity in:

1. Myelinated and unmyelinated axons in laminae I and II of the dorsal horn
2. Approximately 20% of axons in the superficial dorsal horn
3. Vascular endothelium and Schwann cells of the sciatic nerve[14][9]

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

The spinal cord dorsal horn represents a critical site for taurine’s antinociceptive actions, where it modulates synaptic transmission through multiple receptor systems.

Glycine Receptor Activation

Taurine is a potent agonist at glycine receptors (GlyRs) in the substantia gelatinosa (SG), the primary site of nociceptive processing:

1. High efficacy at GlyRs: In rat SG neurons, taurine demonstrates higher efficacy than glycine itself on glycine receptors. At 0.3 mM, taurine activates glycine receptors, while at 3 mM it activates both glycine and GABA-A receptors.[15]
2. Chloride conductance: Taurine-induced currents result from increased chloride conductance, producing neuronal hyperpolarization and reduced excitability.[15][16]
3. Concentration-dependent effects: In trigeminal subnucleus caudalis SG neurons, taurine produces concentration-dependent responses with EC₅₀ values of 84.3 μM for depolarization and 723 μM for inward currents.[16]
4. Strychnine sensitivity: Taurine-mediated responses are almost completely blocked by strychnine (2 μM), confirming glycine receptor mediation.[16][17]

GABA-A Receptor Activation

Taurine activates both synaptic and extrasynaptic GABA-A receptors:

1. – Extrasynaptic GABA-A receptor activation: Taurine (1 mM) activates extrasynaptic GABA-A receptor-mediated currents in SG neurons, contributing to tonic inhibition.[16]
2. – Subunit-dependent affinity: Taurine’s affinity for GABA-A receptors depends on subunit composition. It is a more potent agonist at α4β2δ receptors (involved in tonic inhibition) than at α1β2γ2 receptors.[18]
3. – Partial blockade by picrotoxin: Taurine responses are partially blocked by picrotoxin (50 μM), indicating GABA-A receptor involvement.[16]

Anatomical Distribution in Dorsal Horn

Taurine-like immunoreactivity is most dense in laminae I and II of the dorsal horn, the primary nociceptive processing regions:

1. Approximately 30% of neuronal perikarya at C2, 52% at T6, and 18% at L2 levels exhibit taurine immunoreactivity[14]
2. Taurine is localized to axon terminals containing pleomorphic vesicles forming symmetrical synapses (36.8 particles/μm²), consistent with inhibitory neurotransmission[14]
3. Astrocytes in the dorsal horn also contain taurine (20.9 particles/μm²), suggesting glial involvement in taurine-mediated modulation[14]

Synergistic Effects with COX-2 Inhibitors

Taurine enhances antinociception produced by COX-2 inhibitors in inflammatory pain models. Celecoxib at low doses (0.13-1.3 mg/kg) combined with taurine (300 mg/kg) produces greater reduction in thermo- and mechanonociceptive responses than either drug alone, suggesting complementary peripheral and central mechanisms.[19]

Level 4: Ascending Spinal Pathways and Supraspinal Processing

Taurine modulates ascending pain transmission through effects on glutamatergic signaling and neuronal excitability.

NMDA Receptor Modulation

Taurine directly interacts with NMDA receptors through multiple mechanisms:

1. Reduction of NMDA-mediated responses: In rat medial prefrontal cortex, taurine reduces evoked field potential responses by 41.5 ± 8.3% within the late phase of NMDA-sensitive responses. This effect is prevented by the NMDA antagonist APV but not by the L-type Ca²⁺ channel blocker nifedipine.[20]
2. Spermine-dependent modulation: Taurine inhibits spermine-potentiated specific [³H]MK-801 binding to NMDA receptors by 15-20% in the presence of glycine, and reduces the apparent affinity of NMDA receptors for glycine by 10-fold in the presence of spermine.[20]
3. Multiple interaction sites: Taurine interacts with NMDA receptors through mechanisms distinct from the agonist binding site and glycine binding site, suggesting allosteric modulation.[21][22]

Voltage-Gated Calcium Channel Inhibition

Taurine inhibits calcium influx through multiple voltage-gated calcium channel (VGCC) subtypes:

1. L-type, N-type, and P/Q-type VGCCs: Taurine inhibits glutamate-induced calcium influx through all major VGCC subtypes involved in neurotransmitter release and neuronal excitability.[23][24]
2. Metabotropic-like mechanism: In chromaffin cells, taurine induces dose-dependent inhibition of voltage-dependent calcium channels through a metabotropic-like glycinergic receptor coupled to G-protein activation. This effect is prevented by intracellular GDP-β-S dialysis.[25]
3. Membrane depolarization prevention: Taurine prevents glutamate-induced membrane depolarization, likely through chloride channel opening, thereby reducing voltage-dependent calcium channel activation.[24]

Prevention of Excitotoxicity

Taurine protects ascending pathway neurons from glutamate-induced excitotoxicity:

1. Calcium homeostasis: Taurine reduces glutamate-induced elevation of intracellular Ca²⁺ to basal levels and prevents the sustained calcium elevation that triggers excitotoxic cascades.[22]
2. Anti-apoptotic effects: Taurine prevents glutamate-induced apoptosis by maintaining Bcl-2 levels and preventing calpain-mediated Bcl-2 cleavage.[23]
3. ER stress reduction: Taurine reduces endoplasmic reticulum stress associated with excitotoxicity, contributing to neuronal survival.[26]

Level 5: Thalamic and Cortical Processing and Pain Perception

Taurine exerts significant modulatory effects on thalamic relay neurons and cortical processing of pain signals.

Thalamic Modulation

Taurine is a potent regulator of thalamocortical relay neuron excitability:

1. Extrasynaptic GABA-A receptor activation: Low concentrations of taurine (10-100 μM) reduce the excitability of ventrobasal (VB) thalamic neurons by activating extrasynaptic GABA-A receptors (α4β2δ subtype) involved in tonic inhibition.[18]
2. Reduced neuronal firing: Taurine decreases neuronal input resistance and firing frequency in thalamic relay neurons, reducing the transmission of nociceptive signals to cortex.[18]
3. Endogenous regulation: Taurine transport inhibitors enhance tonic inhibition in thalamic neurons, suggesting that endogenous taurine functions as a physiological regulator of thalamic excitability.[18]
4. Developmental regulation: The amplitude of taurine-evoked currents is larger in neurons from adult mice than juvenile mice, indicating developmental regulation of taurine sensitivity.[18]

Cortical Processing

Taurine modulates cortical pain processing, particularly in the insular cortex:

1. Insular cortex modulation: Both taurine and endomorphin-1 suppress delayed broad negative evoked field potentials in the anterior insular cortex (upper layer 5) by partially inhibiting the NMDA receptor system.[27]
2. Analgesic effects: Taurine markedly delays tail-flick response in rats, indicating supraspinal analgesic effects beyond spinal mechanisms.[27]
3. Neuromodulatory role: Taurine functions as a neuromodulator in cortical circuits, regulating excitatory-inhibitory balance through effects on both glutamatergic and GABAergic transmission.[2]

Cognitive and Affective Dimensions of Pain

Taurine’s effects on cortical function may influence the cognitive and affective dimensions of pain:

1. Prevention of age-related cognitive decline: Taurine supplementation prevents age-dependent decline of cognitive functions, which may be relevant to chronic pain-related cognitive impairment.[28]
2. Neuroprotection: Taurine’s neuroprotective effects in cortical regions may preserve normal pain processing and prevent maladaptive plasticity associated with chronic pain.[26]

Level 6: Descending Pain Modulation

Taurine influences descending pain modulatory systems through multiple mechanisms.

GABAergic and Glycinergic Enhancement

Taurine enhances inhibitory neurotransmission in descending modulatory pathways:

1. GABA receptor agonism: Taurine is an agonist at GABA-A receptors with an EC₅₀ of 116 μM in cerebellar granule cells, compared to 3.7 μM for GABA itself. Both taurine and homotaurine (a taurine analog) have similar efficacy in activating native GABA-A receptors.[29]
2. Strengthening of inhibitory transmission: In the anteroventral cochlear nucleus, taurine strengthens both GABAergic and glycinergic neurotransmission without cross-inhibition, suggesting additive effects on inhibitory tone.[30]
3. Tonic inhibition enhancement: Taurine’s activation of extrasynaptic GABA-A receptors provides sustained tonic inhibition that may enhance descending inhibitory control.[18]

Cholinergic Mechanisms

Taurine interacts with cholinergic systems involved in descending modulation:

1. Muscarinic receptor involvement: Taurine’s analgesic effects involve muscarinic receptor activity. The combination of taurine with morphine attenuates both morphine analgesic tolerance and dependence through muscarinic receptor-dependent mechanisms.[4]
2. Acetylcholinesterase modulation: Taurine affects brain acetylcholinesterase activity in relation to muscarinic receptor function, suggesting modulation of cholinergic tone in descending pathways.[4]

Opioid System Interactions

Taurine demonstrates important interactions with the endogenous opioid system:

1. Attenuation of morphine tolerance: Combination of taurine with morphine is an effective strategy to attenuate both morphine analgesic tolerance and dependence.[4]
2. Endomorphin-like effects: Taurine and endomorphin-1 produce similar suppression of evoked field potentials in the insular cortex through NMDA receptor inhibition, suggesting convergent mechanisms with endogenous opioid peptides.[27]
3. Reduced withdrawal syndrome: Taurine attenuates morphine withdrawal syndrome, indicating modulation of opioid-dependent neural circuits.[4]

Neurotransmitter Balance

Taurine regulates the balance between excitatory and inhibitory neurotransmission in descending pathways:

1. Glutamate-GABA balance: Taurine plays an important role in modulating glutamate and GABA neurotransmission, preventing excitotoxicity and maintaining appropriate inhibitory tone.[28]
2. Metabotropic taurine receptors: Evidence supports the presence of metabotropic taurine receptors negatively coupled to phospholipase C (PLC) signaling through inhibitory G proteins, providing an additional mechanism for modulating neuronal excitability.[26]

Taurine demonstrates comprehensive effects across all six levels of pain processing, with particularly strong evidence for its actions at the spinal cord dorsal horn (Level 3) through glycine and GABA-A receptor activation. The convergence of multiple mechanisms—including receptor-mediated inhibition, calcium homeostasis regulation, membrane stabilization, and neuroprotection—positions taurine as a multifaceted modulator of pain processing with potential therapeutic applications in neuropathic and inflammatory pain conditions.

Table 3.1: Taurine Effects Across Pain Processing Levels – Comprehensive Overview

Pain Processing Level	Primary Mechanisms	Key Molecular Targets	Effect Strength	Evidence Quality	Clinical Relevance
Level 1: Peripheral Nociception	TRPV1 modulation; Ca²⁺ homeostasis correction; anti-inflammatory cytokine reduction; muscarinic receptor activation	TRPV1, muscarinic receptors, TNF-α, IL-6, COX-2	Moderate	Preclinical (animal models)	Diabetic neuropathy, inflammatory pain
Level 2: Primary Afferent Transmission	Nerve conduction preservation; axonal protection via PI3K/Akt/mTOR; myelin protection via NGF/Akt/GSK3β; membrane stabilization	K⁺/Cl⁻ channels, Na⁺/K⁺-ATPase, Schwann cells	Strong	Preclinical (diabetic models)	Diabetic peripheral neuropathy
Level 3: Spinal Dorsal Horn	Glycine receptor agonism; GABA-A receptor activation; enhanced inhibitory neurotransmission; Cl⁻ conductance increase	GlyR, GABA-A (α4β2δ), strychnine-sensitive receptors	Strong	Preclinical + intrathecal studies	Neuropathic pain, central sensitization
Level 4: Ascending Pathways	NMDA receptor modulation; VGCC inhibition (L, N, P/Q-type); excitotoxicity prevention; Ca²⁺ homeostasis	NMDA-R, VGCCs, Bcl-2, calpain	Strong	Preclinical	Chronic pain, excitotoxic injury
Level 5: Thalamic/Cortical	Extrasynaptic GABA-A activation; tonic inhibition enhancement; cortical NMDA modulation	α4β2δ GABA-A, NMDA-R, thalamic relay neurons	Moderate	Preclinical (slice preparations)	Pain perception modulation
Level 6: Descending Modulation	GABAergic/glycinergic enhancement; opioid system interaction; muscarinic receptor modulation	GABA-A, GlyR, muscarinic-R, opioid system	Moderate	Preclinical (behavioral)	Opioid-sparing, tolerance prevention

This table summarizes taurine’s multi-level effects on pain processing, highlighting that the strongest evidence exists at Levels 2–4 (primary afferent transmission, spinal dorsal horn, and ascending pathways), while peripheral, thalamic/cortical, and descending modulation effects show moderate strength with primarily preclinical evidence.

Taurine Pain Processing Reference List

Section 1 – References

Taurine: A Regulator of Cellular Redox Homeostasis and Skeletal Muscle Function. Seidel U, Huebbe P, Rimbach G. Molecular Nutrition & Food Research. 2019;63(16):e1800569. doi:10.1002/mnfr.201800569.
Taurine and Its Analogs in Neurological Disorders: Focus on Therapeutic Potential and Molecular Mechanisms. Jakaria M, Azam S, Haque ME, et al. Redox Biology. 2019;24:101223. doi:10.1016/j.redox.2019.101223.
Taurine and Astrocytes: A Homeostatic and Neuroprotective Relationship. Ramírez-Guerrero S, Guardo-Maya S, Medina-Rincón GJ, et al. Frontiers in Molecular Neuroscience. 2022;15:937789. doi:10.3389/fnmol.2022.937789.
Taurine Regulation of Neuroendocrine Function. El Idrissi A. Advances in Experimental Medicine and Biology. 2019;1155:977-985. doi:10.1007/978-981-13-8023-5_81.
Congenital Taurine Deficiency in Mice Is Associated With Reduced Sensitivity to Nociceptive Chemical Stimulation. Lötsch J, Hummel T, Warskulat U, et al. Neuroscience. 2014;259:63-70. doi:10.1016/j.neuroscience.2013.11.037.
Profiling Inflammatory and Oxidative Stress Biomarkers Following Taurine Supplementation: A Systematic Review and Dose-Response Meta-Analysis of Controlled Trials. Faghfouri AH, Seyyed Shoura SM, Fathollahi P, et al. European Journal of Clinical Nutrition. 2022;76(5):647-658. doi:10.1038/s41430-021-01010-4.
Effects of Oral Taurine Supplementation on Cardiometabolic Risk Factors: A Meta-Analysis and Systematic Review of Randomized Clinical Trials. Nie Z, Liu Y, Zhang M, et al. Nutrition Reviews. 2025;:nuaf220. doi:10.1093/nutrit/nuaf220.
Taurine Alleviates Kidney Injury in a Thioacetamide Rat Model by Mediating Nrf2/Ho-1, NQO-1, and MAPK/NF-κB Signaling Pathways. Ghanim AMH, Farag MRT, Anwar MA, et al. Canadian Journal of Physiology and Pharmacology. 2022;100(4):352-360. doi:10.1139/cjpp-2021-0488.
Taurine Alleviates Experimental Colitis by Enhancing Intestinal Barrier Function and Inhibiting Inflammatory Response Through TLR4/NF-κB Signaling. Zheng J, Zhang J, Zhou Y, et al. Journal of Agricultural and Food Chemistry. 2024;72(21):12119-12129. doi:10.1021/acs.jafc.4c00662.
Effects of Pre- And Post-Supplementation of Taurine in the Hippocampus of a Gerbil Model of Transient Global Cerebral Ischemia. Sabuj MSS, Han SC, Park BY, Tae HJ, Nam SM. International Journal of Molecular Sciences. 2026;27(3):1341. doi:10.3390/ijms27031341.
Taurine as a Natural Antioxidant: From Direct Antioxidant Effects to Protective Action in Various Toxicological Models. Surai PF, Earle-Payne K, Kidd MT. Antioxidants (Basel, Switzerland). 2021;10(12):1876. doi:10.3390/antiox10121876.
Taurine Inhibits KDM3a Production and Microglia Activation in Lipopolysaccharide-Treated Mice and BV-2 Cells. Liu K, Zhu R, Jiang H, et al. Molecular and Cellular Neurosciences. 2022;122:103759. doi:10.1016/j.mcn.2022.103759.
Taurine Protects Dopaminergic Neurons in a Mouse Parkinson’s Disease Model Through Inhibition of Microglial M1 Polarization. Che Y, Hou L, Sun F, et al. Cell Death & Disease. 2018;9(4):435. doi:10.1038/s41419-018-0468-2.
Taurine Reduces Microglia Activation in the Brain of Aged Senescence-Accelerated Mice by Increasing the Level of TREM2. Ahmed S, Ma N, Kawanokuchi J, et al. Scientific Reports. 2024;14(1):7427. doi:10.1038/s41598-024-57973-4.
Protective Effects of Taurine Against Chemical and Natural Compound-Induced Toxicity: Mechanistic Insights and Therapeutic Potential. Keshavarzi M, Razavi BM, Naraki K, Hosseinzadeh H. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;:10.1007/s00210-025-04513-0. doi:10.1007/s00210-025-04513-0.
Protective Role of Taurine Against Oxidative Stress (Review). Baliou S, Adamaki M, Ioannou P, et al. Molecular Medicine Reports. 2021;24(2):605. doi:10.3892/mmr.2021.12242.
The Role of Taurine in Mitochondria Health: More Than Just an Antioxidant. Jong CJ, Sandal P, Schaffer SW. Molecules (Basel, Switzerland). 2021;26(16):4913. doi:10.3390/molecules26164913.
Role of Mitochondria and Endoplasmic Reticulum in Taurine-Deficiency-Mediated Apoptosis. Jong CJ, Ito T, Prentice H, Wu JY, Schaffer SW. Nutrients. 2017;9(8):E795. doi:10.3390/nu9080795.

Section 2 – References

Taurine Inhibits TRPV-Dependent Activity to Overcome Oxidative Stress in Caenorhabditis Elegans. Moriuchi M, Nakano Y, Tsurekawa Y, et al. Biological & Pharmaceutical Bulletin. 2018;41(11):1672-1677. doi:10.1248/bpb.b18-00370.
Effects of TRPV1 Activation by Capsaicin and Endogenous N-Arachidonoyl Taurine on Synaptic Transmission in the Prefrontal Cortex. Zhang M, Ruwe D, Saffari R, Kravchenko M, Zhang W. Frontiers in Neuroscience. 2020;14:91. doi:10.3389/fnins.2020.00091.
Taurine Replacement Attenuates Hyperalgesia and Abnormal Calcium Signaling in Sensory Neurons of STZ-D Rats. Li F, Obrosova IG, Abatan O, et al. American Journal of Physiology. Endocrinology and Metabolism. 2005;288(1):E29-36. doi:10.1152/ajpendo.00168.2004.
Comparative Investigation of Analgesic Tolerance to Taurine, Sodium Salicylate and Morphine: Involvement of Peripheral Muscarinic Receptors. Akbari E, Beheshti F, Zarmehri HA, et al. Neuroscience Letters. 2023;795:137041. doi:10.1016/j.neulet.2022.137041.
Profiling Inflammatory and Oxidative Stress Biomarkers Following Taurine Supplementation: A Systematic Review and Dose-Response Meta-Analysis of Controlled Trials. Faghfouri AH, Seyyed Shoura SM, Fathollahi P, et al. European Journal of Clinical Nutrition. 2022;76(5):647-658. doi:10.1038/s41430-021-01010-4.
Effects of Oral Taurine Supplementation on Cardiometabolic Risk Factors: A Meta-Analysis and Systematic Review of Randomized Clinical Trials. Nie Z, Liu Y, Zhang M, et al. Nutrition Reviews. 2025;:nuaf220. doi:10.1093/nutrit/nuaf220.
Taurine Inhibits KDM3a Production and Microglia Activation in Lipopolysaccharide-Treated Mice and BV-2 Cells. Liu K, Zhu R, Jiang H, et al. Molecular and Cellular Neurosciences. 2022;122:103759. doi:10.1016/j.mcn.2022.103759.
Taurine as a Natural Antioxidant: From Direct Antioxidant Effects to Protective Action in Various Toxicological Models. Surai PF, Earle-Payne K, Kidd MT. Antioxidants (Basel, Switzerland). 2021;10(12):1876. doi:10.3390/antiox10121876.
Depletion of Taurine in Experimental Diabetic Neuropathy: Implications for Nerve Metabolic, Vascular, and Functional Deficits. Pop-Busui R, Sullivan KA, Van Huysen C, et al. Experimental Neurology. 2001;168(2):259-72. doi:10.1006/exnr.2000.7591.
Taurine Ameliorates Axonal Damage in Sciatic Nerve of Diabetic Rats and High Glucose Exposed DRG Neuron by PI3K/Akt/mTOR-dependent Pathway. Zhang M, Shi X, Luo M, et al. Amino Acids. 2021;53(3):395-406. doi:10.1007/s00726-021-02957-1.
Taurine Protects Against Myelin Damage of Sciatic Nerve in Diabetic Peripheral Neuropathy Rats by Controlling Apoptosis of Schwann Cells via NGF/Akt/GSK3β Pathway. Li K, Shi X, Luo M, et al. Experimental Cell Research. 2019;383(2):111557. doi:10.1016/j.yexcr.2019.111557.
Excitability Modulation by Taurine: Action on Axon Membrane Permeabilities. Gruener R, Bryant HJ. The Journal of Pharmacology and Experimental Therapeutics. 1975;194(3):514-21.
Osmotically-Induced Nerve Taurine Depletion and the Compatible Osmolyte Hypothesis in Experimental Diabetic Neuropathy in the Rat. Stevens MJ, Lattimer SA, Kamijo M, et al. Diabetologia. 1993;36(7):608-14. doi:10.1007/BF00404069.
A Quantitative Light and Electron Microscopic Analysis of Taurine-Like Immunoreactivity in the Dorsal Horn of the Rat Spinal Cord. Lee IS, Renno WM, Beitz AJ. The Journal of Comparative Neurology. 1992;321(1):65-82. doi:10.1002/cne.903210107.
Taurine Activates Glycine and Gamma-Aminobutyric Acid a Receptors in Rat Substantia Gelatinosa Neurons. Wu J, Kohno T, Georgiev SK, et al. Neuroreport. 2008;19(3):333-7. doi:10.1097/WNR.0b013e3282f50c90.
Activation of Glycine and Extrasynaptic GABA(A) Receptors by Taurine on the Substantia Gelatinosa Neurons of the Trigeminal Subnucleus Caudalis. Nguyen TT, Bhattarai JP, Park SJ, Han SK. Neural Plasticity. 2013;2013:740581. doi:10.1155/2013/740581.
Antinociceptive Effect of Intrathecal Administration of Taurine in Rat Models of Neuropathic Pain. Terada T, Hara K, Haranishi Y, Sata T. Canadian Journal of Anaesthesia = Journal Canadien d’Anesthesie. 2011;58(7):630-637. doi:10.1007/s12630-011-9504-8.
Taurine Is a Potent Activator of Extrasynaptic GABA(A) Receptors in the Thalamus. Jia F, Yue M, Chandra D, et al. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2008;28(1):106-15. doi:10.1523/JNEUROSCI.3996-07.2008.
Taurine Enhances Antinociception Produced by a COX-2 Inhibitor in an Inflammatory Pain Model. de Rienzo-Madero B, Coffeen U, Simón-Arceo K, et al. Inflammation. 2013;36(3):658-64. doi:10.1007/s10753-012-9589-4.
Modes of Direct Modulation by Taurine of the Glutamate NMDA Receptor in Rat Cortex. Chan CY, Sun HS, Shah SM, et al. European Journal of Pharmacology. 2014;728:167-75. doi:10.1016/j.ejphar.2014.01.025.
Direct Interaction of Taurine With the NMDA Glutamate Receptor Subtype via Multiple Mechanisms. Chan CY, Sun HS, Shah SM, et al. Advances in Experimental Medicine and Biology. 2013;775:45-52. doi:10.1007/978-1-4614-6130-2_4.
Role of Taurine in Regulation of Intracellular Calcium Level and Neuroprotective Function in Cultured Neurons. Chen WQ, Jin H, Nguyen M, et al. Journal of Neuroscience Research. 2001;66(4):612-9. doi:10.1002/jnr.10027.
Mechanism of Neuroprotective Function of Taurine. Wu JY, Wu H, Jin Y, et al. Advances in Experimental Medicine and Biology. 2009;643:169-79. doi:10.1007/978-0-387-75681-3_17.
Mode of Action of Taurine as a Neuroprotector. Wu H, Jin Y, Wei J, et al. Brain Research. 2005;1038(2):123-31. doi:10.1016/j.brainres.2005.01.058.
Modulation of Calcium Channels by Taurine Acting via a Metabotropic-Like Glycine Receptor. Albiñana E, Sacristán S, Martín del Río R, Solís JM, Hernández-Guijo JM. Cellular and Molecular Neurobiology. 2010;30(8):1225-33. doi:10.1007/s10571-010-9574-0.
Role of Taurine in the Central Nervous System. Wu JY, Prentice H. Journal of Biomedical Science. 2010;17 Suppl 1:S1. doi:10.1186/1423-0127-17-S1-S1.
Neuropsychopharmacological Actions of Taurine. Banerjee SP, Ragnauth A, Chan CY, et al. Advances in Experimental Medicine and Biology. 2013;775:3-18. doi:10.1007/978-1-4614-6130-2_1.
Taurine Regulation of Neuroendocrine Function. El Idrissi A. Advances in Experimental Medicine and Biology. 2019;1155:977-985. doi:10.1007/978-981-13-8023-5_81.
GABA Receptors as Plausible Molecular Targets and Mediators for Taurine and Homotaurine Actions. Meera P, Uusi-Oukari M, Lipshutz GS, Wallner M. Frontiers in Pharmacology. 2023;14:1271203. doi:10.3389/fphar.2023.1271203.
Interaction Between Taurine and GABA(A)/glycine Receptors in Neurons of the Rat Anteroventral Cochlear Nucleus. Song NY, Shi HB, Li CY, Yin SK. Brain Research. 2012;1472:1-10. doi:10.1016/j.brainres.2012.07.001.

Section 3

Taurine: Pain Processing Effects vs. Direct Tissue-Modifying Effects

Pain Processing Effects:

Taurine exerts analgesic effects primarily through glycine receptor (GlyR) activation and modulation of inhibitory neurotransmission. Intrathecal taurine (100-800 μg) alleviated mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia in both CCI and diabetic neuropathy rat models. The antinociceptive effects were completely reversed by strychnine (glycine receptor antagonist), confirming glycinergic mediation.[26]

Taurine activates both glycine receptors and extrasynaptic GABA-A receptors on substantia gelatinosa neurons of the trigeminal subnucleus caudalis, producing non-desensitizing membrane depolarizations with EC₅₀ of 84.3 μM. Responses were partially blocked by picrotoxin (GABA-A antagonist) and almost completely blocked by strychnine, indicating dual receptor involvement in orofacial pain modulation.[27]

In the anterior cingulate cortex (ACC), taurine microinjection diminishes neuropathic nociception by decreasing autotomy score and incidence and delaying onset. This effect was antagonized by strychnine, confirming GlyR-A involvement in the affective component of pain processing.[28]

Taurine demonstrates analgesic synergy with other agents. Acute administration of taurine-sodium salicylate combination produces more potent analgesia than either agent alone, mediated via peripheral muscarinic receptors. Combination of taurine and morphine attenuates both morphine analgesic tolerance and dependence.[29]

In diabetic neuropathy, taurine replacement reduces hyperalgesia and abnormal calcium signaling in sensory neurons. Taurine corrected injury-dependent decreases in intracellular Ca²⁺ recovery, normalized caffeine and ATP-induced Ca²⁺ transients in DRG neurons, and prevented reductions in mechanical and thermal withdrawal thresholds—effects independent of blood glucose correction.[30]

Taurine has been described as a potentially valuable analgesic agent that markedly delays tail-flick response and suppresses delayed broad negative evoked field potentials in anterior insular cortex by partially inhibiting the NMDA receptor system.[31]

Direct Tissue-Modifying Effects:

Taurine demonstrates significant chondroprotective effects in both human chondrocytes and animal OA models. In human OA chondrocytes, taurine alleviates H₂O₂-induced endoplasmic reticulum stress, inhibits ER stress markers (GRP78, GADD153, Caspase-12), restores chondrocyte viability and Collagen II synthesis, and inhibits apoptosis.[32]

In ACLT+MMx-induced OA rats, taurine injection significantly relieved OA symptoms in a dose- and time-dependent manner—alleviating secondary mechanical allodynia, decreasing hind limb weight-bearing alterations, and inhibiting knee swelling. Histopathological analysis showed taurine inhibited matrix loss and cartilage degeneration by suppressing MMP-3 and CHOP expression.[33]

In primary human articular chondrocytes, taurine promotes chondrocyte growth, enhances GAG and collagen accumulation, increases expression of cartilage-specific markers (aggrecan, collagen II, SOX9), and decreases collagen I (dedifferentiation marker)—indicating taurine inhibits chondrocyte dedifferentiation and maintains the chondrogenic phenotype.[34]

Taurine promotes cartilaginous differentiation of mesenchymal stem cells—5 mM taurine enhanced GAG accumulation and upregulated collagen II, aggrecan, and SOX9 expression while reducing collagen I, promoting and maintaining chondrogenesis.[35]

A systematic review of preclinical studies on taurine for rheumatoid arthritis found that taurine and its derivatives (taurine-chloramine, taurine-bromamine) control RA by reducing inflammation, suppressing oxidative stress, and inducing apoptosis of inflammatory cells.

However, no clinical studies have been conducted for taurine in RA or OA.[36]

Taurine also has bone-protective effects—it protects osteocytes against oxidative stress-induced cell death and potently downregulates sclerostin (Sost) and Dkk1, inhibitors of the Wnt/β-catenin signaling pathway important for bone formation.[37]

In diabetic peripheral neuropathy, taurine protects against myelin damage by controlling Schwann cell apoptosis via the NGF/Akt/GSK3β pathway, and ameliorates axonal damage in sciatic nerve and DRG neurons via the PI3K/Akt/mTOR pathway.[38][39]

Mechanism	Pain Processing	Tissue Modification	References
Glycine receptor (GlyR) activation	Alleviates mechanical allodynia/hyperalgesia; blocked by strychnine	None	[1], [2]
Extrasynaptic GABA-A receptor activation	Modulates orofacial nociception in trigeminal subnucleus caudalis	None	[1]
NMDA receptor partial inhibition	Suppresses evoked field potentials in insular cortex	None	[2]
Ca²⁺ signaling normalization in DRG	Attenuates hyperalgesia; restores Ca²⁺ transients	None	[3]
ER stress alleviation (↓GRP78, GADD153, Caspase-12)	Indirect	↓Chondrocyte apoptosis; ↑Collagen II synthesis	[4]
MMP-3 and CHOP suppression	Alleviates secondary mechanical allodynia	↓Matrix loss; ↓cartilage degeneration	[5]
Chondrogenic phenotype maintenance	None	↑Aggrecan, Collagen II, SOX9; ↓Collagen I; ↑GAG	[6]
NGF/Akt/GSK3β pathway (Schwann cells)	Protects myelin; improves nerve conduction	None	[7]
Nrf2/HO-1 activation	↓Neuroinflammation in brain/spinal cord	Indirect antioxidant	[8]

Key Distinctions:

Taurine offers a unique mechanism profile among the nutraceuticals reviewed, acting primarily through glycine receptor activation. The complete reversal of taurine’s antinociceptive effects by strychnine (glycine receptor antagonist) in both CCI and diabetic neuropathy models confirms this mechanism. Taurine also activates extrasynaptic GABA-A receptors and partially inhibits NMDA receptors, providing multiple inhibitory neurotransmission targets.
The normalization of calcium signaling in DRG neurons in diabetic neuropathy is particularly relevant—taurine corrects injury-dependent decreases in intracellular Ca²⁺ recovery and normalizes caffeine and ATP-induced Ca²⁺ transients, effects independent of blood glucose correction.This suggests direct neuroprotective effects rather than metabolic correction.
A notable finding is taurine’s synergy with morphine and attenuation of morphine tolerance—combination of taurine and morphine attenuates both analgesic tolerance and dependence, suggesting potential for opioid-sparing strategies. The modulation of the affective component of pain via glycine receptors in the anterior cingulate cortex adds another dimension not seen with other nutraceuticals.
For tissue modification, taurine’s ability to maintain the chondrogenic phenotype (↑aggrecan, collagen II, SOX9; ↓collagen I) and promote MSC chondrogenesis suggests regenerative potential. The dual protection of both cartilage and neural structures (Schwann cells via NGF/Akt/GSK3β; DRG axons via PI3K/Akt/mTOR) is unique among the nutraceuticals reviewed and particularly relevant for diabetic patients with both OA and peripheral neuropathy.

However:

The complete absence of clinical trials for taurine in pain or arthritis represents a significant translational gap, despite strong preclinical evidence and an excellent safety profile as an endogenous amino acid.

References

The Emerging Role of Quercetin in the Treatment of Chronic Pain. Liu C, Liu DQ, Tian YK, et al. Current Neuropharmacology. 2022;20(12):2346-2353. doi:10.2174/1570159X20666220812122437.
Quercetin Attenuates Diabetic Neuropathic Pain by Inhibiting mTOR/p70S6K Pathway-Mediated Changes of Synaptic Morphology and Synaptic Protein Levels in Spinal Dorsal Horn of Db/Db Mice. Wang R, Qiu Z, Wang G, et al. European Journal of Pharmacology. 2020;882:173266. doi:10.1016/j.ejphar.2020.173266.
Quercetin Relieved Diabetic Neuropathic Pain by Inhibiting Upregulated P2X Receptor in Dorsal Root Ganglia. Yang R, Li L, Yuan H, et al. Journal of Cellular Physiology. 2019;234(3):2756-2764. doi:10.1002/jcp.27091.
Quercetin Ameliorates CFA-Induced Chronic Inflammatory Hyperalgesia via Modulation of ROS-Mediated ERK1/2 Signaling and Inhibition of Spinal Glial Activation in Vivo. Kumar S, Vinayak M. Neuromolecular Medicine. 2020;22(4):517-533. doi:10.1007/s12017-020-08609-z.
Quercetin Alleviates Thermal and Cold Hyperalgesia in a Rat Neuropathic Pain Model by Inhibiting Toll-Like Receptor Signaling. Ji C, Xu Y, Han F, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2017;94:652-658. doi:10.1016/j.biopha.2017.07.145.
Quercetin Reduces Inflammation in a Rat Model of Diabetic Peripheral Neuropathy by Regulating the TLR4/MyD88/NF-κB Signalling Pathway. Zhao B, Zhang Q, Liang X, Xie J, Sun Q. European Journal of Pharmacology. 2021;912:174607. doi:10.1016/j.ejphar.2021.174607.
Quercetin Alleviates Osteoarthritis Pain by Inhibiting Vascular Endothelial Growth Factor a Through Regulating cGAS/STING Pathway. Hu E, Wei Y, Liao T, et al. Journal of Cellular and Molecular Medicine. 2026;30(1):e70992. doi:10.1111/jcmm.70992.
The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women With Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial. Javadi F, Ahmadzadeh A, Eghtesadi S, et al. Journal of the American College of Nutrition. 2017;36(1):9-15. doi:10.1080/07315724.2016.1140093.
Effect of a Dietary Supplement Containing Glucosamine Hydrochloride, Chondroitin Sulfate and Quercetin Glycosides on Symptomatic Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Study. Kanzaki N, Saito K, Maeda A, et al. Journal of the Science of Food and Agriculture. 2012;92(4):862-9. doi:10.1002/jsfa.4660.
Therapeutic Potential of Senolytic Agent Quercetin in Osteoarthritis: A Systematic Review and Meta-Analysis of Preclinical Studies. Yamaura K, Nelson AL, Nishimura H, et al. Ageing Research Reviews. 2023;90:101989. doi:10.1016/j.arr.2023.101989.
Quercetin Modulates Ferroptosis via the SIRT1/Nrf-2/HO-1 Pathway and Attenuates Cartilage Destruction in an Osteoarthritis Rat Model. Ruan H, Zhu T, Wang T, et al. International Journal of Molecular Sciences. 2024;25(13):7461. doi:10.3390/ijms25137461.
Quercetin Attenuates Oxidative Stress-Induced Apoptosis via SIRT1/AMPK-mediated Inhibition of ER Stress in Rat Chondrocytes and Prevents the Progression of Osteoarthritis in a Rat Model. Feng K, Chen Z, Pengcheng L, Zhang S, Wang X. Journal of Cellular Physiology. 2019;234(10):18192-18205. doi:10.1002/jcp.28452.
Quercetin Attenuates the Symptoms of Osteoarthritis in Vitro and in Vivo by Suppressing Ferroptosis via Activation of AMPK/Nrf2/Gpx4 Signaling. Dong S, Li X, Xu G, Chen L, Zhao J. Molecular Medicine Reports. 2025;31(3):60. doi:10.3892/mmr.2024.13425.
Quercetin Alleviates Rat Osteoarthritis by Inhibiting Inflammation and Apoptosis of Chondrocytes, Modulating Synovial Macrophages Polarization to M2 Macrophages. Hu Y, Gui Z, Zhou Y, et al. Free Radical Biology & Medicine. 2019;145:146-160. doi:10.1016/j.freeradbiomed.2019.09.024.
Quercetin as a Promising Intervention for Rat Osteoarthritis by Decreasing M1-Polarized Macrophages via Blocking the TRPV1-mediated P2x7/Nlrp3 Signaling Pathway. Li W, He H, Du M, et al. Phytotherapy Research : PTR. 2024;38(4):1990-2006. doi:10.1002/ptr.8158.
Improving Quercetin Bioavailability: A Systematic Review and Meta-Analysis of Human Intervention Studies. Liu L, Barber E, Kellow NJ, Williamson G. Food Chemistry. 2025;477:143630. doi:10.1016/j.foodchem.2025.143630.
A Pharmacokinetic Study of Different Quercetin Formulations in Healthy Participants: A Diet-Controlled, Crossover, Single- And Multiple-Dose Pilot Study. Solnier J, Zhang Y, Roh K, et al. Evidence-Based Complementary and Alternative Medicine : eCAM. 2023;2023:9727539. doi:10.1155/2023/9727539.
Nicotinamide Riboside, a Form of Vitamin B3 and NAD+ Precursor, Relieves the Nociceptive and Aversive Dimensions of Paclitaxel-Induced Peripheral Neuropathy in Female Rats. Hamity MV, White SR, Walder RY, et al. Pain. 2017;158(5):962-972. doi:10.1097/j.pain.0000000000000862.
What Is Really Known About the Effects of Nicotinamide Riboside Supplementation in Humans. Damgaard MV, Treebak JT. Science Advances. 2023;9(29):eadi4862. doi:10.1126/sciadv.adi4862.
Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-Inflammatory Signatures. Elhassan YS, Kluckova K, Fletcher RS, et al. Cell Reports. 2019;28(7):1717-1728.e6. doi:10.1016/j.celrep.2019.07.043.
NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Yaku K, Nakagawa T. Antioxidants & Redox Signaling. 2023;39(16-18):1133-1149. doi:10.1089/ars.2023.0354.
Mitochondria-Targeted NAD+/O2 Co-Delivery Interpenetrating Network Hydrogel for Respiratory Chain Restoration and Osteoarthritis Therapy. Shen X, Hu J, Wang C, et al. Journal of Controlled Release : Official Journal of the Controlled Release Society. 2025;385:113975. doi:10.1016/j.jconrel.2025.113975.
The Influence of Sirtuin 6 on Chondrocyte Senescence in Osteoarthritis Under Aging: Focusing on Mitochondrial Dysfunction and Oxidative Stress. Zhao H, Wu W. Antioxidants (Basel, Switzerland). 2025;14(10):1228. doi:10.3390/antiox14101228.
Vitamin D Is an Endogenous Partial Agonist of the Transient Receptor Potential Vanilloid 1 Channel. Long W, Fatehi M, Soni S, et al. The Journal of Physiology. 2020;598(19):4321-4338. doi:10.1113/JP279961.
Vitamin D3 Attenuates Neuropathic Pain via Suppression of Mitochondria-Associated Ferroptosis by Inhibiting PKCα/NOX4 Signaling Pathway. Zhang W, Yu S, Jiao B, et al. CNS Neuroscience & Therapeutics. 2024;30(9):e70067. doi:10.1111/cns.70067.
Antinociceptive Effect of Intrathecal Administration of Taurine in Rat Models of Neuropathic Pain. Terada T, Hara K, Haranishi Y, Sata T. Canadian Journal of Anaesthesia = Journal Canadien d’Anesthesie. 2011;58(7):630-637. doi:10.1007/s12630-011-9504-8.
Activation of Glycine and Extrasynaptic GABA(A) Receptors by Taurine on the Substantia Gelatinosa Neurons of the Trigeminal Subnucleus Caudalis. Nguyen TT, Bhattarai JP, Park SJ, Han SK. Neural Plasticity. 2013;2013:740581. doi:10.1155/2013/740581.
Taurine in the Anterior Cingulate Cortex Diminishes Neuropathic Nociception: A Possible Interaction With the Glycine(A) Receptor. Pellicer F, López-Avila A, Coffeen U, Manuel Ortega-Legaspi J, Angel RD. European Journal of Pain (London, England). 2007;11(4):444-51. doi:10.1016/j.ejpain.2006.06.003.
Comparative Investigation of Analgesic Tolerance to Taurine, Sodium Salicylate and Morphine: Involvement of Peripheral Muscarinic Receptors. Akbari E, Beheshti F, Zarmehri HA, et al. Neuroscience Letters. 2023;795:137041. doi:10.1016/j.neulet.2022.137041.
Taurine Replacement Attenuates Hyperalgesia and Abnormal Calcium Signaling in Sensory Neurons of STZ-D Rats. Li F, Obrosova IG, Abatan O, et al. American Journal of Physiology. Endocrinology and Metabolism. 2005;288(1):E29-36. doi:10.1152/ajpendo.00168.2004.
Neuropsychopharmacological Actions of Taurine. Banerjee SP, Ragnauth A, Chan CY, et al. Advances in Experimental Medicine and Biology. 2013;775:3-18. doi:10.1007/978-1-4614-6130-2_1.
Taurine Alleviates Endoplasmic Reticulum Stress in the Chondrocytes From Patients With Osteoarthritis. Bian Y, Wang H, Sun S. Redox Report : Communications in Free Radical Research. 2018;23(1):118-124. doi:10.1080/13510002.2018.1445581.
Taurine Protects Against Knee Osteoarthritis Development in Experimental Rat Models. Bian Y, Zhang M, Wang K. The Knee. 2018;25(3):374-380. doi:10.1016/j.knee.2018.03.004.
Chondroprotective Effects of Taurine in Primary Cultures of Human Articular Chondrocytes. Liu Q, Lu Z, Wu H, Zheng L. The Tohoku Journal of Experimental Medicine. 2015;235(3):201-13. doi:10.1620/tjem.235.201.
Taurine Promotes the Cartilaginous Differentiation of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Vitro. Yao X, Huang H, Li Z, et al. Neurochemical Research. 2017;42(8):2344-2353. doi:10.1007/s11064-017-2252-6.
A Systematic Review of Preclinical Studies on the Efficacy of Taurine for the Treatment of Rheumatoid Arthritis. Malek Mahdavi A, Javadivala Z. Amino Acids. 2021;53(6):783-800. doi:10.1007/s00726-021-02988-8.
Taurine, an Osteocyte Metabolite, Protects Against Oxidative Stress-Induced Cell Death and Decreases Inhibitors of the WNT/Β-Catenin Signaling Pathway. Prideaux M, Kitase Y, Kimble M, O’Connell TM, Bonewald LF. Bone. 2020;137:115374. doi:10.1016/j.bone.2020.115374.
Taurine Protects Against Myelin Damage of Sciatic Nerve in Diabetic Peripheral Neuropathy Rats by Controlling Apoptosis of Schwann Cells via NGF/Akt/GSK3β Pathway. Li K, Shi X, Luo M, et al. Experimental Cell Research. 2019;383(2):111557. doi:10.1016/j.yexcr.2019.111557.
Taurine Ameliorates Axonal Damage in Sciatic Nerve of Diabetic Rats and High Glucose Exposed DRG Neuron by PI3K/Akt/mTOR-dependent Pathway. Zhang M, Shi X, Luo M, et al. Amino Acids. 2021;53(3):395-406. doi:10.1007/s00726-021-02957-1.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.